MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Vertex Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

485.87 0.47

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

481.39

Максимум

493

Ключови измерители

By Trading Economics

Приходи

-132M

913M

Продажби

142M

2.9B

P/E

Средно за сектора

30.42

63.778

EPS

3.98

Марж на печалбата

31.353

Служители

6,100

EBITDA

-99M

1.2B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+2.96% upside

Дивиденти

By Dow Jones

Следващи печалби

5.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

6.8B

127B

Предишно отваряне

485.4

Предишно затваряне

485.87

Настроения в новините

By Acuity

12%

88%

14 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.02.2025 г., 22:11 ч. UTC

Печалби

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31.01.2025 г., 00:19 ч. UTC

Значими двигатели на пазара

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19.12.2024 г., 12:25 ч. UTC

Значими двигатели на пазара

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4.11.2024 г., 21:44 ч. UTC

Печалби

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

1.08.2024 г., 20:45 ч. UTC

Печалби

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11.02.2025 г., 21:12 ч. UTC

Печалби

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11.02.2025 г., 14:21 ч. UTC

Печалби

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10.02.2025 г., 21:12 ч. UTC

Печалби

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10.02.2025 г., 21:12 ч. UTC

Печалби

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10.02.2025 г., 21:11 ч. UTC

Печалби

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10.02.2025 г., 21:04 ч. UTC

Печалби

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10.02.2025 г., 21:04 ч. UTC

Печалби

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10.02.2025 г., 21:02 ч. UTC

Печалби

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10.02.2025 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10.02.2025 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10.02.2025 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10.02.2025 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31.01.2025 г., 09:59 ч. UTC

Горещи акции

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4.11.2024 г., 22:21 ч. UTC

Печалби

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4.11.2024 г., 21:25 ч. UTC

Печалби

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4.11.2024 г., 21:03 ч. UTC

Печалби

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

4.11.2024 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX

4.11.2024 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 3Q Net $1.05B >VRTX

4.11.2024 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX

26.09.2024 г., 14:20 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1.08.2024 г., 20:30 ч. UTC

Печалби

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1.08.2024 г., 20:03 ч. UTC

Печалби

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1.08.2024 г., 20:02 ч. UTC

Печалби

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1.08.2024 г., 20:02 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

Сравнение с други в отрасъла

Ценова промяна

Vertex Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

2.96% нагоре

12-месечна прогноза

Среден 499.09 USD  2.96%

Висок 591 USD

Нисък 320 USD

Според 27 анализатори от Wall Street, предложили 12-месечна ценова цел за Vertex Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

27 ratings

16

Купи

10

Задържане

1

Продай

Техническа оценка

By Trading Central

480.95 / 505Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

14 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.